Gastrointestinal Cancers (Issue 4)

A panel of expert clinical investigators discussed details of several treatments and a dozen patient cases involving gastric, colorectal, and pancreatic cancer at a satellite meeting of the 2015 ASCO GI Cancers Symposium.

In the largest patient population study to date, Mayo Clinic investigators have identified new genetic predictors of toxicity to colon cancer treatment, but the study has some caveats.

Two-thirds of patients with biliary tract tumors may harbor genomic alterations that could potentially be targets in precision medicine, according to a study led by Jeffrey S. Ross, MD.

Comparable test results were shown with both urine and plasma molecular assays in a blinded, retrospective study.

A post-hoc analysis of the CORRECT trial showed that patients with mCRC who had PFS >4 months, experienced AEs at rates broadly similar to those in the overall trial population.

Eric Van Cutsem, MD, PhD, discusses the challenges of using chemotherapy to treat patients with gastric cancer.

Kei Muro, MD, discusses phase II and III trials which examine pembrolizumab as a treatment for patients with advanced gastric cancer.

Manish A Shah, MD, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma.

Chiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.